Literature DB >> 28970157

Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals.

X M Nie1, Y S Li2, Z W Yang3, H Wang3, S Y Jin3, Y Jiao1, M L Metersky4, Y Huang5.   

Abstract

OBJECTIVES: Studies on treatment of community-acquired pneumonia (CAP) in China are scarce. We performed a study to investigate empiric antibiotic practices for patients hospitalized with CAP in China and the risk factors for treatment failure.
METHODS: Data were collected from a national Chinese hospitalization database. Adult patients who were diagnosed with CAP between 1 October 2014 and 30 September 2015 were identified. We studied initial empiric antibiotic regimens, microbiologic sampling, treatment failure, in-hospital mortality and length of hospital stay.
RESULTS: We included 18 043 adult patients from 185 hospitals who met all the study inclusion criteria. The most common initial antibiotic regimen for CAP was monotherapy with a fluoroquinolone (14.8%, 2671/18 043). The most common initial antibiotic (used alone or in combination with other antibiotics) was levofloxacin (15.7%, 4597/29 278 (this denominator represents the total number of initial antibiotics)). The microbiologic sampling rate was 26.9% (4851/18 043). A total of 4050 (22.4%) of 18 043 patients experienced treatment failure. Multivariate logistic regression demonstrated that older age, male sex, coexisting lung cancer and use of regimens not covering atypical pathogens were risk factors for treatment failure. In-hospital mortality was 2.1% (380/18 043). The median hospital length of stay was 11 days (interquartile range, 8-15 days).
CONCLUSIONS: Patients receiving Chinese guideline-adherent regimens had better outcomes, and atypical pathogen active regimens were associated with a lower treatment failure rate and shorter length of hospital stay.
Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic therapy; Atypical pathogen covering; Community-acquired pneumonia; Length of stay; Treatment failure

Mesh:

Substances:

Year:  2017        PMID: 28970157     DOI: 10.1016/j.cmi.2017.09.014

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  4 in total

1.  Empiric Antibiotic Therapy in the Treatment of Community-acquired Pneumonia in a General Hospital in Saudi Arabia.

Authors:  Jaffar A Al-Tawfiq; Hisham Momattin; Kareem Hinedi
Journal:  J Glob Infect Dis       Date:  2019 Apr-Jun

2.  Etiology of Community-Acquired Pneumonia Requiring Hospital Admission in Adults with and Without Cancers: A Single-Center Retrospective Study in China.

Authors:  Xinxin Wang; Haihua Zhang; Tao Zhang; Lei Pan; Ke Dong; Ming Yang; Ruina Ma; Yujuan Li
Journal:  Infect Drug Resist       Date:  2020-06-08       Impact factor: 4.003

3.  Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.

Authors:  Mingye Zhao; Zhuoyuan Chi; Xingming Pan; Yue Yin; Wenxi Tang
Journal:  Int J Environ Res Public Health       Date:  2022-04-15       Impact factor: 4.614

4.  Association between hospital-acquired pneumonia and proton pump inhibitor prophylaxis in patients treated with glucocorticoids: a retrospective cohort study based on 307,622 admissions in China.

Authors:  Xufeng Mao; Zhangwei Yang
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.